Bayer’s Asundexian FXIa Inhibitor Demonstrates Reduction in Ischemic Stroke in OCEANIC-STROKE Study

April 17, 2026—The results from the OCEANIC-STROKE study were published by Mukul Sharma, MD, et al in The New England Journal of Medicine (NEJM; 2026;394:1467-1479).

Bayer’s Asundexian Reduced Recurrent Ischemic Stroke in OCEANIC-STROKE

February 19, 2026—Bayer recently reported that its oral factor XIa inhibitor asundexian reduced the risk of recurrent ischemic stroke in patients after noncardioembolic ischemic stroke or high-risk transient ischemic attack (TIA), meeting the primary efficacy endpoint of the phase 3 OCEANIC-STROKE trial, according to the company’s announcement.

iVascular’s ANGIODAPT Trial Completes Enrollment

February 2, 2026—iVascular announced the completion of patient recruitment for the ANGIODAPT trial, which is evaluating ischemic and bleeding outcomes after implantation of the iVascular Angiolite drug-eluting stent and abbreviated dual antiplatelet therapy (DAPT).

Concept’s Abluminus NP Polymer-Free DES and Antiplatelet Strategies Studied in STARS-DAPT

January 23, 2026—Concept Medical Inc., announced the enrollment of the first patients in the STARS DAPT randomized controlled trial (RCT) of ST-segment elevation myocardial infarction (STEMI) treated with the company’s Abluminus np—a polymer-free, sirolimus-based, nanocarrier eluting stent—and a P2Y12 inhibitor-based single antiplatelet strategy after a short dual antiplatelet therapy (DAPT) versus conventional DAPT.

STRIVE Evaluates Intracoronary Low-Dose Alteplase During PCI

November 24, 2025—The STRIVE trial evaluated a novel strategy to prevent and treat microvascular obstruction and reduce major cardiovascular events in patients with large-territory ST-elevated myocardial infarction (STEMI) and high thrombus burden undergoing primary percutaneous coronary intervention (PCI).

FDA Begins Real-Time Reporting of Adverse Event Data

August 25, 2025—The FDA announced it has commenced daily publication of adverse event data from the FDA Adverse Event Reporting System (FAERS).

XyloCor Begins EXACT-2 Trial of Catheter-Based XC001 Gene Therapy to Treat CAD

July 25, 2025—XyloCor Therapeutics, a biopharmaceutical company developing therapies for cardiovascular disease, recently announced the first patient has been enrolled in the EXACT-2 trial.

GE HealthCare’s Optison Ultrasound-Enhancing Agent Approved for Pediatric Indication

May 13, 2025—GE HealthCare announced that the FDA has approved a pediatric indication for the company’s Optison (perflutren protein-type A microspheres injectable suspension, USP) ultrasound-enhancing agent (UEA).

Analysis From TRITAVI Registry Compares SAPT and DAPT After TAVR

May 1, 2025—The Society for Cardiovascular Angiography & Interventions (SCAI) announced that findings from an analysis of the Transfusion Requirements in Transcatheter Aortic Valve Implantation (TRITAVI) registry demonstrated that single antiplatelet therapy (SAPT) after transcatheter aortic valve replacement (TAVR) is associated with a significantly lower incidence of 6-month mortality and major bleeding risk compared to dual antiplatelet therapy (DAPT).

Biotronik’s Orsiro Mission DES Approved for New Indications in Europe

January 14, 2025—Biotronik announced the approval of two new indications for the Orsiro Mission drug-eluting stent (DES): (1) 1-month dual antiplatelet therapy (DAPT) for high-bleeding-risk patients and (2) treatment of calcified lesions.

CLEAR SYNERGY Finds Routine Colchicine Administration After Acute MI Did Not Improve Outcomes

October 29, 2024—Results from the CLEAR SYNERGY trial showed that both acute and long-term use of colchicine—an oral medication that reduces inflammation—did not reduce cardiovascular death, myocardial infarction (MI), stroke, or ischemia-driven revascularization.

Abbott HeartMate 3 LVAD Gains FDA Approval for Aspirin-Free Regimen

August 21, 2024—Abbott announced that the FDA approved a change to the label for the company’s HeartMate 3 left ventricular assist device (LVAD) that eliminates aspirin as part of routine patient management.

J&J’s Xarelto Shows Reduced Risk of Bleeding and Adverse Events in Analysis of PIONEER AF-PCI Data

April 12, 2024—Johnson & Johnson (J&J) recently announced findings from a new analysis of the PIONEER AF-PCI clinical trial data.

ULTIMATE-DAPT Evaluates Ticagrelor Monotherapy After 1 Month of DAPT Post PCI in ACS Patients

April 7, 2024—The ULTIMATE-DAPT study showed that patients who have had (or are at risk for) a heart attack and stopped taking aspirin alongside ticagrelor at 1 month after percutaneous coronary intervention (PCI) experienced a significantly reduced risk of clinically meaningful bleeding with no increased risk of clotting-related adverse events at 12 months, compared with patients who continued taking aspirin and ticagrelor for a full year.

Esperion’s Nexletol and Nexlizet Receive FDA Approval for Broader Indications

March 29, 2024—Esperion recently announced that the FDA has approved new broad label expansions for Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe) tablets that include indications for cardiovascular risk reduction and expanded low-density lipoprotein cholesterol (LDL-C) lowering in both primary and secondary prevention patients.

Vaxxinity’s Cholesterol Vaccine Candidate Shown to Lower LDL-C in Preclinical Data

February 15, 2024—Vaxxinity, Inc. announced the publication of data demonstrating that the company’s VXX-401 reproducibly lowers low-density lipoprotein cholesterol (LDL-C) in nonhuman primates.

iVascular’s ANGIODAPT RCT of Abbreviated DAPT After PCI Begins Enrollment

December 14, 2023—iVascular announced the initiation of its first randomized trial of an abbreviated dual antiplatelet therapy (DAPT) regimen after implantation of the company’s Angiolite drug-eluting stent to treat patients with coronary artery disease (CAD).

Abbott’s HeartMate 3 LVAD Studied With Aspirin-Free Antiplatelet Regimen in ARIES

November 27, 2023—Abbott recently announced data showing that advanced heart failure patients living with the company’s HeartMate 3 left ventricular assist device (LVAD) who did not receive aspirin as part of their anticoagulation regimen experienced fewer complications from bleeding and were associated with reduced hospital visits compared to patients who received aspirin daily after implantation of the device.

Biosense Webster Study Compares Catheter Ablation Versus Drug Therapy for HF Risk in AFib Patients

October 5, 2023—Biosense Webster, Inc., part of Johnson & Johnson MedTech, announced new data from a company-funded study that sought to compare the risk of heart failure incidence among patients with atrial fibrillation (AFib) treated with catheter ablation versus antiarrhythmic drugs (AAD).

Johnson & Johnson Announces New Pharmaceutical and MedTech Business Segment Branding

September 14, 2023—Johnson & Johnson announced that it is uniting both its medtech and pharmaceutical segments under the Johnson & Johnson brand name.